Nano vaccine based on two-dimensional black phosphorus as well as preparation method and application of nano vaccine
Through a nanovaccine based on two-dimensional black phosphorus, combined with photothermal therapy and immunotherapy, and using PEG-MAL-modified black phosphorus nanosheets to load antigen proteins, the problem of incomplete photothermal therapy and immunosuppression in the prior art has been solved. It achieves efficient anti-tumor effects and activation of immune responses, prolongs survival and reduces the risk of tumor recurrence.
Patent Information
- Application Number
- CN202411231825.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-29
AI Technical Summary
The existing photothermal therapy and immunotherapy are incomplete in cancer treatment, prone to recurrence, and immunosuppression is more common.
Using a nanovaccine based on two-dimensional black phosphorus, the PEG-MAL-modified black phosphorus nanosheets are loaded with antigens and induce photothermal treatment under near-infrared laser irradiation to release tumor-related antigens, combining the capture and presentation of PEG-MAL. function, activate immune response.
In situ tumor ablation and systemic immune response induction were achieved, significantly improved the anti-tumor effect, extended the survival of mice, and activated memory cells when tumor recurrence, reducing the risk of tumor recurrence.
Smart Images

Figure CN119033923A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of nanomedicine, and in particular relates to a nanovaccine based on two-dimensional black phosphorus, and a preparation method, application and preparation method thereof. Background Art
[0002] As an emerging cancer treatment strategy, immunotherapy has shown significant efficacy in clinical practice. Its main methods include checkpoint inhibitor therapy (such as anti-PD-1 / PD-L1 and anti-CTLA-4 therapy), T cell adoptive immunotherapy and vaccine therapy. Although these methods have been successful in certain types of cancer, they generally face the challenges of low immune response rate and difficulty in completely ablating local tumors. Therefore, finding more effective immunotherapy strategies remains the focus of current research.
[0003] Nanovaccines are a new type of immunotherapy that has developed rapidly in recent years. By loading antigens or immunomodulators onto nanomaterials, nanovaccines can significantly improve the stability and immunogenicity of antigens and enhance the immune system's ability to recognize and attack tumor cells. The advantages of nanovaccines lie in their efficient delivery system and ability to precisely regulate immune responses, which gives them broad application prospects in tumor immunotherapy.
[0004] Photothermal therapy is a physical therapy that generates heat energy under the irradiation of light of a specific wavelength through photosensitizers, thereby locally killing tumor cells. In recent years, two-dimensional nanomaterials such as black phosphorus have become a hot topic in photothermal therapy research due to their high photothermal conversion efficiency and good biocompatibility. Photothermal therapy can not only directly kill tumor cells, but also induce tumor cells to release antigens, further activate the immune system, and have a profound impact on the tumor microenvironment.
[0005] Combination therapy strategies combine the advantages of immunotherapy, nanovaccines, and photothermal therapy, aiming to overcome the limitations of single treatments. By using them together, these treatments can synergize with each other and enhance the anti-tumor effect. Combination therapy is not only expected to improve the overall efficacy of treatment, but also reduce the risk of tumor recurrence, becoming an important direction for future cancer treatment. By integrating different treatment methods, combination therapy has shown great potential in tumor treatment, providing new ideas and methods for conquering the difficult problem of cancer. Existing studies have shown that black phosphorus (BP) has the potential to be a photosensitizer and can effectively kill cancer cells under the irradiation of near-infrared lasers. In addition, polyethylene glycol maleimide (PEG-MAL) has been shown to function as an antigen capture agent, which can effectively capture and deliver antigens. Summary of the invention
[0006] The purpose of the present invention is to solve the problems of incomplete treatment effect, easy recurrence, immunosuppression and the like of existing photothermal therapy and immunotherapy.
[0007] In order to solve the above technical problems, the present invention adopts the following technical solutions: A two-dimensional black phosphorus-based nanovaccine comprises BPNSs modified with PEG-MAL and loaded with antigen protein.
[0008] Preferably, the antigen protein comprises a specific antigen protein derived from tumor cells.
[0009] In the design of the present invention, two-dimensional black phosphorus nanosheets are used as a multifunctional platform, acting as a photosensitizer to induce photothermal effect, and combined with PEG-MAL to improve the stability of black phosphorus and in situ capture and presentation of tumor-associated antigens, while loading proteins from tumor cells to increase the level of antigen expression to enhance the immune response. When the BP-PEG-MAL@protein drug designed by the present invention is injected into the tumor, the tumor is irradiated with NIR laser to induce photothermal therapy (PTT), achieve in situ thermal ablation of cancer cells, and then release tumor-associated antigens. PEG-MAL bound to BP will capture this part of the antigen in situ, and present it to antigen presenting cells (APCs) in combination with in vitro bound tumor proteins, thereby playing a vaccine-like role and inducing a strong immune response in the body. In addition, metastatic tumors will be cleared by the activation of immune cells such as helper T lymphocytes and cytotoxic T lymphocytes. This strategy has shown significant therapeutic effects on both in situ breast cancer and metastatic breast cancer in mice, effectively promoting tumor ablation and prolonging the survival of mice. In addition, the photothermal therapy combined with immunotherapy based on BP-PEG-MAL@protein still showed a strong immune response and anti-tumor effect when tumor cells were inoculated again 151 days after the initial ablation of mouse tumors. Therefore, black phosphorus nanosheets with photothermal properties and the ability to capture and present tumor-derived protein antigens can play a vaccine-like role, induce abscotpal effect, and show excellent anti-tumor effects in tumor treatment.
[0010] A method for preparing the above-mentioned two-dimensional black phosphorus-based nanovaccine comprises: A. Dissolve black phosphorus crystal powder in an amide organic solvent, crush it with ultrasonic vibration, and then dilute it by centrifugation to obtain a BPNSs aqueous solution; B. uniformly mixing the BPNSs aqueous solution and the NH2-PEG-MAL aqueous solution to obtain a mixed solution, and then firstly ultrasonicating and then stirring to obtain a BP-PEG-MAL solution; C. Mix the BP-PEG-MAL solution with the antigen protein, shake, blow and incubate, then centrifuge, and mix the precipitate evenly with a buffer to obtain the two-dimensional black phosphorus-based nanovaccine.
[0011] Preferably, including: A. dissolving the black phosphorus crystal powder in the amide organic solvent, performing ultrasonic crushing three times by an ultrasonic cell crusher, the crushing power includes 800-855W, and the crushing time includes 45-50 min each time, and this process is carried out under ice water bath conditions; then using an ultrasonic cleaner to ultrasonically mix the mixture at 660-800W for 1 hour, and performing the first centrifugation, the speed includes 2000 rpm, the time includes 10-15 min, and the precipitate and the supernatant are separated after centrifugation, and the obtained supernatant is subjected to the second centrifugation, the speed includes 12000-14000 rpm, the time includes 10-15 min, and the precipitate and the supernatant are separated after centrifugation, and the obtained precipitate is subjected to the third centrifugation, the speed includes 12000-14000 rpm, the time includes 10-15 min, and the precipitate is retained after centrifugation, and diluted with deionized water to obtain the BPNSs aqueous solution, which is stored at 4°C in the dark; B. Dissolve NH2-PEG-MAL in pure water to obtain the NH2-PEG-MAL aqueous solution, mix it with the BPNSs aqueous solution, ultrasonicate it at 660-800W for 30-35 min at room temperature, and then stir it for 4 h in the dark with a magnetic stirrer at a speed of 600-700 rpm. After centrifugation, retain the precipitate and dissolve it again. Generally, pure water is used to dissolve the precipitate again, and it is stored in the dark at 4°C to obtain the BP-PEG-MAL solution; C. Mixing the tumor cells with the BPNSs aqueous solution and cultivating them, and releasing the antigen protein under the action of near-infrared light; adding the BP-PEG-MAL solution to the antigen protein, shaking and blowing, placing it in an incubator for 24 hours, centrifuging it at a speed of 12000-14000 rpm for 10-15 minutes, discarding the supernatant, and mixing the precipitate evenly with a buffer solution to obtain the two-dimensional black phosphorus-based nanovaccine, which was stored at 4°C for future use.
[0012] Preferably, in step C, the operation of releasing the antigen protein comprises: The tumor cells were inoculated into a cell plate and incubated under the conditions of 5% CO2 and 37°C for 24 hours, washed twice with buffer, 100 μL of the BPNSs aqueous solution of the same concentration was added to each well, and a culture medium containing 10% serum was added to make the total volume 2 mL, incubated in an incubator for 6 hours, rinsed twice with buffer, and the power used included 1.0 W / cm 2The cells were irradiated with 808 nm near-infrared light for 10 min. After irradiation, 2-3 mL of serum-free culture medium was added to each well and placed in an incubator for 48 h. The supernatant in the cell plate was aspirated into a centrifuge tube and centrifuged at 2000 rpm for 5 min. The supernatant was aspirated to obtain the antigen protein and stored at 4°C for later use.
[0013] Preferably, the amide organic solvent includes NMP; the buffer includes PBS; the serum includes FBS; and the culture medium includes DMEM.
[0014] In step A, the black phosphorus crystal powder is soluble in amide organic solvents. Amide organic solvents similar to NMP can be used as dispersants for BP, but BP has the best dispersion stability in NMP and should be considered as a better choice.
[0015] Preferably, in step A, the mass volume ratio of the black phosphorus crystal powder to the amide organic solvent is 2-12 mg: 5-6 mL; in step B, the mass ratio of the NH2-PEG-MAL to the black phosphorus in the BPNSs aqueous solution is 10:1; in step C, the tumor cells are cultured at 3-5 × 10 5 Seed in 12-well cell plates.
[0016] Preferably, the molecular weight of PEG in the NH2-PEG-MAL is 2000 or less.
[0017] Preferably, the black phosphorus in the BPNSs aqueous solution is a two-dimensional black phosphorus nanosheet of 100-200 nm; the concentration of the BPNSs aqueous solution includes 5 mg / mL-10 mg / mL; the concentration of the BP-PEG-MAL solution includes 5 mg / mL-10 mg / mL.
[0018] The concentration of the BPNSs aqueous solution and the BP-PEG-MAL solution is preferably controlled in the range of 5 mg / mL to 10 mg / mL. Too high a concentration is not convenient for subsequent dilution, while too low a concentration tends to accelerate the rate of oxidation and degradation of black phosphorus.
[0019] An application of the above-mentioned two-dimensional black phosphorus-based nanovaccine in the preparation of drugs for preventing or treating cancer.
[0020] The implementation of the present invention has the following beneficial effects: 1. The present invention combines long molecule PEG-MAL with BP to enhance the stability of BP.
[0021] 2. The present invention uses PEG-MAL to capture antigens released by necrotic cancer cells after photothermal therapy and presents them to antigen-presenting cells to induce the body's immune response.
[0022] 3. The present invention combines BP-PEG-MAL with proteins released after cancer cell necrosis through photothermal therapy to achieve personalized drug preparation.
[0023] 4. The present invention can ablate tumors in situ, reducing the disadvantage of poor treatment effect of single immune response on in situ tumors.
[0024] 5. The present invention combines photothermal therapy and immunotherapy to achieve thermal ablation of in situ tumors and induction of systemic immune responses, effectively eliminating potential lesions and metastatic tumors.
[0025] 6. The drug prepared by the present invention has good biocompatibility and anti-tumor effect.
[0026] 7. The present invention can personalize cancer treatment plans and improve the effect of drug treatment.
[0027] 8. The present invention can effectively activate the body's immune response and induce the differentiation of memory cells, so that cancer cells can be quickly killed when they recur, reducing tumor recurrence and prolonging the patient's survival. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The analysis pictures of the products in each stage of preparation. Among them: (a) is the TEM picture of BPNSs; (b) is the TEM picture of BP-PEG-MAL; (c) is the TEM picture of BP-PEG-MAL@protein; (d) is the AFM picture of BPNSs; (e) is the AFM picture of BP-PEG-MAL; (f) is the AFM picture of BP-PEG-MAL@protein.
[0029] Figure 2 This is the EDS diagram of BP-PEG-MAL@protein.
[0030] Figure 3 Zeta potential diagrams of NH2-PEG-MAL (column 1), BP (column 2), BP-PEG-MAL (column 3) and BP-PEG-MAL@protein (column 4).
[0031] Figure 4 Comparison of the stability of products at different stages. (a) Comparison of BP, BP-PEG-MAL and BP-PEG-MAL@protein at room temperature on day 0 and day 7; (b) UV spectra of BP at room temperature on day 0 and day 7; (c) UV spectra of BP-PEG-MAL at room temperature on day 0 and day 7; (d) UV spectra of BP-PEG-MAL@protein at room temperature on day 0 and day 7.
[0032] Figure 5 The BP-PEG-MAL@protein at 808 nm and 1.0 W / cm 2 Temperature change curve after 10 minutes of heating under laser irradiation.
[0033] Figure 6 BP-PEG-MAL@protein at 808 nm and 1.0 W / cm 2 Temperature variation curve of heating under 5 laser on / off cycles under laser irradiation.
[0034] Figure 7 The figure is a comparison of the in vitro protein antigen loading and DC2.4 activation capacity of different concentrations of BP-PEG-MAL. Among them: (a) The content of tumor-derived protein antigens bound in vitro by different concentrations of BP-PEG-MAL; TNF-α cytokine (b) and IL-6 cytokine (c) released by DC2.4 after the drug was co-cultured with DC2.4.
[0035] Figure 8 Schematic diagram of cell survival rate after co-culture of BP-PEG-MAL@protein with 4T1 at different BP concentrations.
[0036] Fig. 9 Live-dead double staining images after BP-PEG-MAL@protein was co-cultured with 4T1 at different concentrations.
[0037] Fig.10 Schematic diagram of the killing effect of different concentrations of BP-PEG-MAL@protein on 4T1 cells after 808 nm laser irradiation for 10 minutes, using the live-dead double staining kit for staining.
[0038] Fig.11 Schematic diagram of the killing effect of different concentrations of BP-PEG-MAL@protein on 4T1 cells after 808 nm laser irradiation for 10 minutes, and the cell survival rate was measured using trypan blue.
[0039] Fig.12 The in situ in vivo anti-tumor effect of BP-PEG-MAL@protein was investigated. (a) Schematic diagram of the experimental method for the anti-tumor effect of BP-PEG-MAL@protein; (b) 4T1 tumor-bearing mice were injected with PBS, BP-PEG, BP-PEG-MAL or BP-PEG-MAL@protein and then irradiated with 808 nm laser (10 min, 1.0 W cm −2) under infrared thermal imaging; (c) 4T1 tumor-bearing mice injected with PBS, BP-PEG, BP-PEG-MAL, or BP-PEG-MAL@protien were irradiated with 808 nm laser (10 min, 1.0 W cm −2 ) under different conditions; (d) tumor growth curves of tumor-bearing mice after different treatments (n = 5, mean±SD); (e) survival curves of tumor-bearing mice after different treatments; (f) tumor growth curves of tumor-bearing mice re-injected with tumor cells 151 days after the initial treatment.
[0040] Fig.13 The results are as follows: (a) Schematic diagram of the experimental method for the anti-tumor effect of BP-PEG-MAL@protein; (b) 4T1 tumor-bearing mice injected with BP-PEG-MAL or BP-PEG-MAL@protein and then irradiated with 808 nm laser (10 min, 1.0 W cm −2 ) under infrared thermal imaging; (c) 4T1 tumor-bearing mice injected with BP-PEG-MAL or BP-PEG-MAL@protien and irradiated with 808 nm laser (10 min, 1.0 W cm −2 ) under different treatments; (d) proximal tumor growth curves of tumor-bearing mice after different treatments (n = 5, mean±SD); (e) distal tumor growth curves of tumor-bearing mice after different treatments (n = 5, mean±SD); (f) survival curves of tumor-bearing mice after different treatments. DETAILED DESCRIPTION
[0041] In order to make the objectives, technical solutions and advantages of the present invention more clear, the present invention will be further described in detail below with reference to the accompanying drawings.
[0042] Example 1 1.1 Synthesis of two-dimensional black phosphorus Two-dimensional black phosphorus was prepared according to the liquid phase exfoliation method. 60 mg of black phosphorus crystal powder and 30 mL of NMP liquid were added to a centrifuge tube and mixed. Ultrasonic cell crushing was performed three times by an ultrasonic cell crusher (Ningbo Xinzhi Biotechnology Co., LTD (Ningbo, China)), with a crushing power of 855W, and each crushing was performed for 50 min. This process was carried out under ice-water bath conditions. The mixture was mixed evenly by ultrasonic cleaning (Xiaomei Ultrasonic Instrument Co., Ltd (Suzhou, China)) at 800W for 1 hour. The obtained black mixture was centrifuged for the first time at a speed of 2000rpm for 15 min, and the black phosphorus precipitate and supernatant were separated after centrifugation. The obtained supernatant was separated from the solvent NMP and black phosphorus by the second and third centrifugations, and the two-dimensional black phosphorus precipitate was retained to improve the purity. The speed was 14000 rpm for 15 min. The precipitate was diluted with deionized water and stored in the dark at 4 ℃.
[0043] 1.2 Synthesis of BP-PEG-MAL The present invention combines negatively charged black phosphorus with positively charged NH2-PEG-MAL by an electrostatic bonding method to prepare BP-PEG-MAL. Add an appropriate amount of pure water to 10 mg of NH2-PEG-MAL to dissolve and mix with 1 mg of diluted BP liquid, and ultrasonicate at room temperature for 35 min at 800W. Then stir in the dark for 4 h with a magnetic stirrer at a speed of 700 rpm. After centrifugal purification, retain the precipitate and dissolve it again, and store it in the dark at 4°C.
[0044] 1.3 Synthesis of BP-PEG-MAL@protein MCF-7 cells were cultured at 3 × 10 5 Plant in a 12-well plate and incubate for 24 h at 5% CO2 and 37°C. Wash twice with PBS, add 100 μL of BP solution of the same concentration to each well, add DMEM containing FBS to make the total volume 2 mL, and incubate in an incubator for 6 h. Preliminary experiments have determined that incubation for 6 h allows MCF-7 cells to have sufficient time to endocytose BP. Rinse twice with PBS to remove BP that has not been endocytosed and other waste materials that may be produced by cells. Then use a power of 1.0 W / cm 2Irradiate with 808 nm near-infrared light for 10 min. After BP is internalized by MCF-7 cells, BP can heat up and kill MCF-7 cells under near-infrared laser irradiation. After the MCF-7 cells are killed, the tumor-derived protein antigens inside will be released and become the source of protein on BP-PEG-MAL@protein. After irradiation, add 2 mL of serum-free DMEM to each well and place it in an incubator for 48 h. Pipette the supernatant from the cell plate into a centrifuge tube, centrifuge at 2000 rpm for 5 min, and pipette 0.5 mL of the supernatant containing the antigen and store it at 4°C for later use. Add different concentrations of BP-PEG-MAL solution to each centrifuge tube, shake and blow, and place it in an incubator for 24 h. Centrifuge at 13000 rpm for 12 min, discard the supernatant, mix the precipitate evenly with PBS (2.25 mg BP-PEG-MAL corresponds to 1 mL PBS), and obtain BP-PEG-MAL@protein, which is stored at 4°C for later use.
[0045] Example 2 1.1 Synthesis of two-dimensional black phosphorus Two-dimensional black phosphorus was prepared according to the liquid phase exfoliation method. 10 mg of black phosphorus crystal powder was added to 25 mL of NMP liquid in a centrifuge tube and mixed. Ultrasonic cell crushing was performed three times by an ultrasonic cell crusher (Ningbo Xinzhi Biotechnology Co., LTD (Ningbo, China)), with a crushing power of 800 W, and each crushing was performed for 48 min. This process was carried out under ice-water bath conditions. The mixture was mixed evenly by ultrasonic cleaning (Xiaomei Ultrasonic Instrument Co., Ltd (Suzhou, China)) at 660 W for 1 hour. The obtained black mixture was centrifuged for the first time at a speed of 2000 rpm for 10 min, and the black phosphorus precipitate and supernatant were separated after centrifugation. The obtained supernatant was separated from the solvent NMP and black phosphorus by the second and third centrifugation, and the two-dimensional black phosphorus precipitate was retained to improve the purity. The speed was 12000 rpm for 10 min. The precipitate was diluted with deionized water and stored in the dark at 4 ℃.
[0046] 1.2 Synthesis of BP-PEG-MAL The present invention combines negatively charged black phosphorus with positively charged NH2-PEG-MAL by an electrostatic bonding method to prepare BP-PEG-MAL. Add an appropriate amount of pure water to 10 mg of NH2-PEG-MAL to dissolve and mix with 1 mg of diluted BP liquid, and ultrasonicate at 660W for 33 min at room temperature. Then stir in a dark place for 4 h with a magnetic stirrer at a speed of 600 rpm. After centrifugal purification, retain the precipitate and dissolve it again, and store it in a dark place at 4 °C.
[0047] 1.3 Synthesis of BP-PEG-MAL@protein MDA-MB-231 cells were plated at 4 × 10 5 Plant in a 12-well plate and incubate for 24 hours at 5% CO2 and 37°C. Wash twice with PBS, add 100 μL of BP solution of the same concentration to each well, add DMEM containing FBS to make the total volume 2mL, and incubate in an incubator for 6 hours. Preliminary experiments have determined that incubation for 6 hours allows 4T1 cells to have sufficient time to endocytose BP. Rinse twice with PBS to remove BP that has not been endocytosed and other waste materials that may be produced by other cells. Then use a power of 1.0 W / cm 2 Irradiate with 808 nm near-infrared light for 10 min. After the MDA-MB-231 cells internalize BP, BP can heat up and kill the MDA-MB-231 cells under the irradiation of near-infrared laser. After the MDA-MB-231 cells are killed, the internal tumor-derived protein antigens will be released and become the source of protein on BP-PEG-MAL@protein. After irradiation, add 3 mL of serum-free DMEM to each well and put it in the incubator for 48 h. Pipette the supernatant from the cell plate into a centrifuge tube, centrifuge at 2000 rpm for 5 min, and aspirate 0.5 mL of the supernatant containing the antigen and store it at 4°C for later use. Add different concentrations of BP-PEG-MAL solution to each centrifuge tube, shake and blow, and put it in the incubator for 24 h. Centrifuge at 13,000 rpm for 12 min, discard the supernatant, and mix the precipitate evenly with PBS (2.25 mg BP-PEG-MAL corresponds to 1 mL PBS) to obtain BP-PEG-MAL@protein, which was stored at 4°C for future use.
[0048] Example 3 1.1 Synthesis of two-dimensional black phosphorus Two-dimensional black phosphorus was prepared according to the liquid phase exfoliation method. 50 mg of black phosphorus crystal powder and 25 mL of NMP liquid were added to a centrifuge tube and mixed. Ultrasonic cell crushing was performed three times by an ultrasonic cell crusher (Ningbo Xinzhi Biotechnology Co., LTD (Ningbo, China)), with a crushing power of 810W, and each crushing was performed for 45 min. This process was carried out under ice-water bath conditions. The mixture was mixed evenly by ultrasonic cleaning (Xiaomei Ultrasonic Instrument Co., Ltd (Suzhou, China)) at 760W for 1 hour. The obtained black mixture was centrifuged for the first time at a speed of 2000rpm for 12 min, and the black phosphorus precipitate and supernatant were separated after centrifugation. The obtained supernatant was separated from the solvent NMP and black phosphorus by the second and third centrifugations, and the two-dimensional black phosphorus precipitate was retained to improve the purity. The speed was 13000 rpm for 12 min. The precipitate was diluted with deionized water and stored in the dark at 4 ℃.
[0049] 1.2 Synthesis of BP-PEG-MAL The present invention combines negatively charged black phosphorus with positively charged NH2-PEG-MAL by an electrostatic bonding method to prepare BP-PEG-MAL. Add an appropriate amount of pure water to 10 mg of NH2-PEG-MAL to dissolve and mix with 1 mg of diluted BP liquid, and ultrasonicate at 765W for 30 min at room temperature. Then stir in a dark place with a magnetic stirrer for 4 h at a speed of 650 rpm. After centrifugal purification, retain the precipitate and dissolve it again, and store it in a dark place at 4 °C.
[0050] 1.3 Synthesis of BP-PEG-MAL@protein 4T1 cells were plated at 5 × 10 5 Plant in a 12-well plate and incubate for 24 h at 5% CO2 and 37°C. Wash twice with PBS, add 100 μL of BP solution of the same concentration to each well, add DMEM containing FBS to make the total volume 2 mL, and incubate in an incubator for 6 h. Preliminary experiments have determined that incubation for 6 h allows 4T1 cells to have sufficient time to endocytose BP. Rinse twice with PBS to remove BP that has not been endocytosed and other waste materials that may be produced by other cells. Then use a power of 1.0 W / cm 2Irradiate with 808nm near-infrared light for 10 min. After 4T1 cells internalize BP, BP can heat up and kill 4T1 cells under near-infrared laser irradiation. After 4T1 cells are killed, the tumor-derived protein antigens inside will be released and become the source of protein on BP-PEG-MAL@protein. After irradiation, add 2mL of serum-free DMEM to each well and put it in the incubator for 48 h. Pipette the supernatant in the cell plate into a centrifuge tube, centrifuge at 2000 rpm for 5 min, and aspirate 0.5 mL of the supernatant containing antigens and store it at 4℃ for use. Add different concentrations of BP-PEG-MAL solution to each centrifuge tube, shake and blow, and put it in the incubator for 24 h. Centrifuge at 13000 rpm for 12 min, discard the supernatant, mix the precipitate evenly with PBS (2.25 mg BP-PEG-MAL corresponds to 1 mL PBS), and obtain BP-PEG-MAL@protein, which is stored at 4℃ for use.
[0051] 1.4 Stability Analysis The stability of BP-PEG-MAL was analyzed by comparing the UV absorption spectra with BP under different time and conditions. BP and BP-PEG-MAL aqueous solutions with the same concentration were prepared and placed at room temperature and protected from light for 7 days. The UV absorption spectra of the samples at 500-800 nm on day 0 and day 7 were measured by a UV-visible spectrophotometer (UV-1780, Shimadzu, Kyoto, Japan) to compare the BP degradation rates between different materials.
[0052] The photothermal efficiency and photostability of BP, BP-PEG-MAL and BP-PEG-MAL@protein were analyzed by heating experiments and repeated heating experiments. The power used was 1.0 W / cm 2 , 808 nm near-infrared light was used to irradiate different concentrations of BP, BP-PEG-MAL and BP-PEG-MAL@protein for 10 minutes. At the same time, the temperature rise was recorded by a thermal imager (FOTRIC 225Sinfrared thermal imager (Shanghai, China)) to analyze the photothermal effect. In addition, the same concentration of BP, BP-PEG-MAL and BP-PEG-MAL@protein was selected to repeat the heating and cooling process 5 times to analyze the thermal stability of BP, BP-PEG-MAL and BP-PEG-MAL@protein.
[0053] 1.5 In vitro toxicity study of BP-PEG-MAL@protein The cytotoxicity of BP-PEG-MAL@protein was tested by CCK-8 kit. 4T1 cells were plated at 1 × 10 4 The cells were seeded in 96-well plates and incubated in 5% CO 2 The cells were cultured at 37°C for 24 h (BB150, Thermo Fisher Scientific, Waltham, MA). Then, 100 μL of BP-PEG-MAL@protein with different BP concentrations was added to the well plate for co-culture for 24 h. The cell viability was obtained according to the CCK-8 assay instructions. The cells after co-culture were stained with a live-dead double staining kit, and the fluorescence distribution was observed under an inverted fluorescence microscope (Carl Zeiss, Oberkochen, Germany) to assist in analyzing the cytotoxicity of BP-PEG-MAL@protein.
[0054] 1.6 In vitro phototoxicity study of BP-PEG-MAL@protein BP-PEG-MAL@protein co-cultured with 4T1 cells was irradiated with 808 nm near-infrared light, and the cell survival rate was investigated. 4T1 cells were cultured at 5 × 10 5 The cells were grown in 12-well plates in 5% CO 2 The cells were incubated at 37 °C for 24 h. BP-PEG-MAL@protein with different BP concentrations was added to each well and cultured for 6 h. After washing twice with PBS, the cells were digested with trypsin and collected by centrifugation. The power used was 1.0 W / cm 2 The cells were irradiated with 808 nm near-infrared light for 10 min. After irradiation, DMEM without FBS was added and cultured for 2 h. 10 μL of trypan blue was mixed with 10 μL of cell solution, and the cell viability was obtained by counting the cells using a cell counter (Bio-Rad TC20TM Automated Cell Counter (Hercules, CA)). The remaining cell solution was centrifuged at 2000 rpm for 3 min, the supernatant was poured out, PBS was pipetted, and the centrifugation was repeated three times. Finally, the cells were stained with a live-dead double staining kit and photographed under a fluorescence microscope (Leica, Wetzlar, Germany). 1.7 In vitro protein capture and immunostimulatory effects of BP-PEG-MAL The ability of BP-PEG-MAL@protein to capture antigens was measured by BCA protein assay. 1.3 was repeated to obtain BP-PEG-MAL@protein at different BP concentrations, and the content of antigen captured by BP-PEG-MAL at different BP concentrations was measured by BCA protein assay.
[0055] The TNF-α and IL-6 released by DC2.4 cells were measured by ELISA antigen detection method to verify the immune activation ability of BP-PEG-MAL@protein. DC2.4 cells were plated at 5 × 10 5 The cells were incubated in 12-well plates for 24 h. The original culture medium was then aspirated, and 900 μL of serum-free culture medium and 100 μL of BP-PEG-MAL@protein with different BP concentrations were added to each well and incubated for 24 h. The cells were centrifuged at 2000 rpm for 3 min, and the supernatant was retained and stored at -20 °C for later use. The contents of pro-inflammatory cytokines TNF-α and IL-6 were determined by ELISA antigen detection.
[0056] 1.8 Orthotopic tumor animal model 3 × 10 5 4T1 cells. When the tumor volume (width^2 × length / 2) reaches 100 mm 3 At 14:00 p.m., mice were randomly divided into groups according to the instructions and the nanodrug was injected subcutaneously into the tumor. One hour later, the mouse tumor was irradiated with 808 nm laser for 10 min. The tumor volume was measured every 2 days, and the mice were euthanized when the tumor size met the euthanasia criteria. The survival time of the mice was continuously recorded until the conditions for terminating the recording of survival time were met.
[0057] 1.9 Bilateral tumor animal model 3 × 10 5 4T1 cells, 1 × 10 5 4T1 cells. When the tumor volume (width^2 × length / 2) reaches 100 mm 3 At 14:00 p.m., mice were randomly divided into groups according to the instructions and the tumors were subcutaneously injected with nanomedicine. One hour later, the right leg tumor of the mouse was irradiated with 808 nm laser for 10 min. The tumor volume was measured every 2 days, and the mouse was euthanized when the tumor size met the euthanasia criteria. The survival time of the mouse was continuously recorded until the conditions for terminating the recording of survival time were met.
[0058] Effect Example 1 Through TEM, AFM and EDS (such as Figure 1 , Figure 2 As shown in Figure 2, the present invention successfully prepared BP modified with PEG-MAL and TDPAs, namely the product BP-PEG-MAL@protein. EDS images further confirmed the presence of phosphorus and the successful loading of TDPAs.
[0059] Effect Example 2 like Figure 3 As shown, the Zeta potential of NH2-PEG-MAL is positive, and the bare BP is negative. After PEG-MAL is bound to BP, the product BP-PEG-MAL is also negative, but the potential is greater than that of bare BP, indicating the successful binding of PEG-MAL. In addition, protein is negatively charged, so the potential of BP-PEG-MAL loaded with protein is negatively charged, and is more negative than the potential of BP-PEG-MAL. By comparing the Zeta potential, it can be further proved that the final material BP-PEG-MAL@protein prepared by the present invention is successfully loaded with NH2-PEG-MAL and protein.
[0060] Effect Example 3 like Figure 4 As shown in the figure, after PEG-MAL was bound to naked BP, the long molecule PEG-MAL enhanced the stability of BP, and the tumor protein also slowed down the degradation of BP to a certain extent. Compared with naked BP, the BP degradation of BP-PEG-MAL and BP-PEG-MAL@protein after 7 days at room temperature was much less than that of naked BP.
[0061] Effect Example 4 like Figure 5 , Figure 6 As shown in Figure 2, when the BP concentration was 100 μg / mL, BP-PEG-MAL@protein had a strong affinity for PEG-MAL@protein at 808 nm and 1.0 W / cm 2 Under laser irradiation, the temperature can be raised to about 45°C in 10 minutes, which is enough to cause tumor cells to necrotize and release cell contents. At the same time, BP-PEG-MAL@protein showed excellent photothermal stability in repeated heating experiments, indicating that it can be repeatedly irradiated without damaging its photothermal performance, and also proved that BP-PEG-MAL can still play a role in patients after binding to tumor-related proteins in vitro.
[0062] Effect Example 5 like Figure 7As shown, different concentrations of BP-PEG-MAL have different tumor-derived protein antigen loadings. The higher the concentration of BP-PEG-MAL, the more tumor-derived protein antigens it can load. At the same time, BP-PEG-MAL and BP-PEG-MAL@protein were co-cultured with dendritic cells (DC) 2.4, and the concentrations of TNF-α and IL-6 cytokines released by DC2.4 were detected. The results showed that the concentration of pro-inflammatory cytokines increased with the increase of drug concentration. At the same concentration, BP-PEG-MAL@protein had a stronger ability to induce DC2.4 activation than BP-PEG-MAL.
[0063] Effect Example 6 like Figure 8 , Fig. 9 As shown, after the final material BP-PEG-MAL@protein was co-cultured with 4T1 for 24 hours, the cell survival rate at different concentrations of the material was detected using the cck-8 method, and the cultured cells were stained using the Calcein-AM / PI kit to obtain a live-dead double-staining fluorescence image. The observation results show that BP-PEG-MAL@protein at different concentrations has no obvious cytotoxicity, proving that it has good biocompatibility.
[0064] Effect Example 7 like Fig.10 , Fig.11 As shown in the figure, the ability of BP-PEG-MAL@protein to convert light energy into heat energy increases with the increase of concentration. After 4T1 cells were co-cultured with BP-PEG-MAL@protein of different concentrations for 6 hours, they were irradiated with 808 nm near-infrared laser for 10 minutes. The observation results show that the higher the drug concentration, the lower the survival rate of 4T1 cells, which is consistent with the experimental phenomenon that the drug concentration is positively correlated with the temperature increase in the temperature increase experiment.
[0065] Effect Example 8 like Fig.12 As shown in the figure, BP-PEG-MAL@protein showed excellent effect in tumor treatment of mice bearing orthotopic tumors. After 20 days of drug injection, the tumors of the tumor-bearing mice were basically ablated, and two mice were still alive after the end of the survival curve statistics, with a survival time of more than 150 days. Re-injection of tumor cells after 151 days also had a good effect in inhibiting the growth of orthotopic tumors. This shows that BP-PEG-MAL@protein successfully induced the body's immune response in tumor-bearing mice and produced immune memory cells, which effectively inhibited tumor recurrence and metastasis and improved the survival period and quality of life.
[0066] Effect Example 9 like Fig.13 As shown, in this experiment, the present invention simulates the situation of tumor metastasis in tumor-bearing mice by injecting different amounts of tumor cells into the bilateral thighs of mice, and injects drugs and treatment into the proximal tumors of mice. The experimental results show that the tumor-bearing mice treated with BP-PEG-MAL@protein have significant effects on the growth inhibition of both proximal and distal tumors. After 21 days of treatment, the proximal tumors of the tumor-bearing mice were basically ablated, and the growth of the distal tumors was inhibited. At the same time, two tumor-bearing mice treated with BP-PEG-MAL@protein survived after the statistical time of the survival curve ended, and the survival time exceeded 150 days.
[0067] The above description is only a preferred embodiment of the present invention, which certainly cannot be used to limit the scope of the present invention. Therefore, equivalent changes made according to the claims of the present invention are still within the scope of the present invention.
Claims
1. A two-dimensional black phosphorus-based nanovaccine, characterized in that: The method includes modifying BPNSs with PEG-MAL and loading antigen protein.
2. The two-dimensional black phosphorus-based nanovaccine according to claim 1, characterized in that: The antigen protein includes a specific antigen protein derived from tumor cells.
3. A method for preparing a two-dimensional black phosphorus-based nanovaccine according to claim 1, characterized in that: include: A. Dissolve black phosphorus crystal powder in an amide organic solvent, crush it with ultrasonic vibration, and then dilute it by centrifugation to obtain a BPNSs aqueous solution; B. uniformly mixing the BPNSs aqueous solution and the NH2-PEG-MAL aqueous solution to obtain a mixed solution, and then firstly ultrasonicating and then stirring to obtain a BP-PEG-MAL solution; C. Mix the BP-PEG-MAL solution with the antigen protein, shake, blow and incubate, then centrifuge, and mix the precipitate evenly with a buffer to obtain the two-dimensional black phosphorus-based nanovaccine.
4. The method for preparing a two-dimensional black phosphorus-based nanovaccine according to claim 3, characterized in that: include: A. dissolving the black phosphorus crystal powder in the amide organic solvent, performing ultrasonic crushing three times by an ultrasonic cell crusher, the crushing power includes 800-855W, and the crushing time includes 45-50 min each time, and this process is carried out under ice water bath conditions; then using an ultrasonic cleaner to ultrasonically mix the mixture at 660-800W for 1 hour, and performing the first centrifugation, the speed includes 2000 rpm, the time includes 10-15 min, and the precipitate and the supernatant are separated after centrifugation, and the obtained supernatant is subjected to the second centrifugation, the speed includes 12000-14000 rpm, the time includes 10-15 min, and the precipitate and the supernatant are separated after centrifugation, and the obtained precipitate is subjected to the third centrifugation, the speed includes 12000-14000 rpm, the time includes 10-15 min, and the precipitate is retained after centrifugation, and diluted with deionized water to obtain the BPNSs aqueous solution, which is stored at 4°C in the dark; B. Dissolve NH2-PEG-MAL in pure water to obtain the NH2-PEG-MAL aqueous solution, mix it with the BPNSs aqueous solution, ultrasonicate it at 660-800W for 30-35 min at room temperature, stir it in the dark for 4 h with a magnetic stirrer at a speed of 600-700 rpm, retain the precipitate after centrifugation and dissolve it again, store it in the dark at 4°C to obtain the BP-PEG-MAL solution; C. Mixing the tumor cells with the BPNSs aqueous solution and cultivating them, and releasing the antigen protein under the action of near-infrared light; adding the BP-PEG-MAL solution to the antigen protein, shaking and blowing, placing it in an incubator for 24 hours, centrifuging it at a speed of 12000-14000 rpm for 10-15 minutes, discarding the supernatant, and mixing the precipitate evenly with a buffer solution to obtain the two-dimensional black phosphorus-based nanovaccine, which was stored at 4°C for future use.
5. The method for preparing a two-dimensional black phosphorus-based nanovaccine according to claim 4, characterized in that: In step C, the operation of releasing the antigen protein includes: The tumor cells were inoculated into a cell plate and incubated under the conditions of 5% CO2 and 37°C for 24 h, washed twice with buffer, 100 μL of the BPNSs aqueous solution of the same concentration was added to each well, and a culture medium containing 10% serum was added to make the total volume 2 mL, incubated in an incubator for 6 h, rinsed twice with buffer, and the power used included 1.0 W / cm 2 The cells were irradiated with 808 nm near-infrared light for 10 min. After irradiation, 2-3 mL of serum-free culture medium was added to each well and placed in an incubator for 48 h. The supernatant in the cell plate was aspirated into a centrifuge tube and centrifuged at 2000 rpm for 5 min. The supernatant was aspirated to obtain the antigen protein and stored at 4°C for later use.
6. The method for preparing a two-dimensional black phosphorus-based nanovaccine according to claim 5, characterized in that: The amide organic solvent includes NMP; the buffer includes PBS; the serum includes FBS; and the culture medium includes DMEM.
7. The method for preparing a two-dimensional black phosphorus-based nanovaccine according to claim 5, characterized in that: In step A, the mass volume ratio of the black phosphorus crystal powder to the amide organic solvent is 2-12 mg: 5-6 mL; in step B, the mass ratio of the NH2-PEG-MAL to the black phosphorus in the BPNSs aqueous solution is 10:1; in step C, the tumor cells are cultured at 3-5 × 10 5 Seed in 12-well cell plates.
8. The method for preparing a two-dimensional black phosphorus-based nanovaccine according to claim 3, characterized in that: The molecular weight of PEG in the NH2-PEG-MAL is about 2,000.
9. The method for preparing a two-dimensional black phosphorus-based nanovaccine according to claim 3, characterized in that: The black phosphorus in the BPNSs aqueous solution is a two-dimensional black phosphorus nanosheet of 100-200 nm; the concentration of the BPNSs aqueous solution includes 5 mg / mL-10 mg / mL; the concentration of the BP-PEG-MAL solution includes 5 mg / mL-10 mg / mL.
10. An application of the two-dimensional black phosphorus-based nanovaccine according to claim 1, characterized in that: Application in the preparation of drugs for preventing or treating cancer.
Citation Information
Cited By
Two-dimensional black phosphorus hybrid nano-drug based on RC48 protein modification as well as preparation method and application of two-dimensional black phosphorus hybrid nano-drug
CN119868588A
